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nity (Table 1). These initiating factors should, in principal,Mayo Clinic
trigger nearly every inflammatory pathway. It is intuitiveRochester, Minnesota 55905
that a xenograft should induce a severe immune reaction
because of the great diversity of antigens introduced inThe transplantation of cells, tissue, or organs between
the host. However, diversity of antigens is not sufficientdisparate species, that is, “xenotransplantation,” has
to explain the fate of xenografts, as graft outcome onlybeen of increasing interest in the past decade. This
weakly correlates with genetic disparity between donorinterest stems in large part from the possibility that xeno-
and recipient. Indeed, parasites and commensual or-transplantation would address the severe shortage of
ganisms carry far more antigens into the host. The pro-human organs and tissues for transplantation—a prob-
found reaction to a xenograft may be the consequence
lem that severely limits the application of transplantation
of molecular differences between species that exist for
for the treatment of human disease. There are other
other reasons, such as from divergent evolution. If that
advantages of a xenotransplant. A xenotransplant might
were to be the case, one might also expect the strength
be carried out to avoid infection by a human virus. For of the xenogeneic reaction to correlate with increasing
example, the liver and the bone marrow of baboons diversity between the species. However, nearly all spe-
have been transplanted into human subjects in attempts cies of animals and plants reject xenografts, and the
to treat viral hepatitis and AIDS, respectively. A xeno- reaction is not necessarily a function of phylogenetic
transplant can be planned, allowing the pretreatment of distance (Table 2). This suggests the alternative possibil-
the donor or the recipient for such purposes as preven- ity that the xenogeneic reaction may be adaptive.
tion of inflammation, elimination of infectious organisms, The possibility that xenogeneic reactions are adaptive
or induction of immunological tolerance. A xenotrans- may be drawn from an evolutionary perspective. The
plant may derive from animals genetically engineered in rejection of xenografts is manifested by the most primi-
the germline to reduce the risk of rejection or to express tive species of multicellular organisms (Humphreys and
genes of therapeutic value for the recipient. Reinherz, 1994; Muller et al., 1999), suggesting that the
For all of the advantages of xenotransplantation, how- reaction may have arisen as an adaptation of multicellu-
ever, there are also daunting hurdles to success. These larity. As one example, a sponge rejects an allograft or
hurdles include the immune response of the recipient xenograft in approximately 3 days. Rejection of allo-
against the transplant, the potential limitation and the grafts and xenografts by such primitive organisms is
physiologic function of the transplant in a foreign host, mediated by phagocytic cells, coagulation proteins, and
and the possibility that novel infectious organisms might possibly by complement-like proteins, some of the same
be transmitted from the transplant to the recipient. The components that mediate the rejection of xenografts in
potential applications of xenotransplantation and the higher animals (Table 1).
hurdles of conducting xenotransplantation in human pa- What advantage is brought about by the xenogeneic
tients have been the subject of recent reviews (Auchin- reaction? Several hypotheses can be advanced. The
closs and Sachs, 1998; Platt, 1998). xenogeneic reaction could have evolved as a mecha-
We shall summarize the current state of knowledge nism of speciation, maintaining diversity by protecting
regarding the immunological hurdles to xenotransplan- the individual or progeny from damage caused by the
tation. Understanding the nature of these responses presence of a foreign species or their products and/
or by avoiding nonmutually advantageous colonization.may facilitate the development of approaches to over-
Both mechanisms may also, in turn, contribute to thecoming the barrier to xenotransplantation. Understand-
establishment of reproductive isolation, which is funda-ing the natural and elicited immune responses to xeno-
mental to speciation.transplantation may also yield new insights into the
Protection against engraftment of stem cells may wellfunction and control of immunity.
have been a strong adaptive drive for the xenogeneicXenotransplants are opposed by natural and elicited
reaction. In fact, xenogeneic reactions to stem cells areimmune responses. We use the term “natural immunity”
more vigorous than to other cellular transplants betweento depict responses preexistent to xenotransplantation
the same species. For example, inoculation of porcineas opposed to responses elicited by the xenograft.
hematopoietic stem cells was recently shown to engen-Some of the responses that occur before xenotransplan-
der a procoagulant response in baboons akin to dissem-tation, such as the production of xenoreactive natural
inated intravascular coagulation (Ierino et al., 1998).antibodies, are not present at birth but appear later and
Mutations in the cytokines or receptors mediating in-may, in fact, be adaptive responses to microorganisms.
teraction between stem cells and their environment may
well be of advantage in inhibiting colonization by cells




Table 1. Components of Immune and Inflammatory Systems that Initially Recognize a Xenograft
Component Component Mechanism Target Cell HARa AVRa
Complement alternative pathway factor H C3b 1 ?
Complement regulatory proteins CD55, CD46, CD57 C3/C4, C3/C4, C2/C9 1 ?
Natural antibody Ab Gala1,3Gal 1/2 1
Neutrophil integrins 2 1/2
Macrophage lectin saccharide 2 1/2
Platelet IL-1a IL-1R 2 1/2
Thrombin thrombomodulin, TFPI 2 1/2
NK cell KIR, lectin, FcR MHC class I, Gala1,3Gal, 2 1/2
IgFc
KIR, killer inhibitory receptor; TFPI, tissue factor pathway inhibitor; HAR, hyperacute rejection; AVR, acute vascular rejection.
a Components thought to initiate HAR or AVR are listed as 1; components for which there is an association but no proof are listed as 1/2.
The Elements of Inflammation and Immunity highly susceptible to complement-mediated injury (Platt
et al., 1990; Atkinson et al., 1991). Such susceptibilitythat Oppose Xenotransplantation
Practically every element of immune and inflammatory has been mimicked experimentally by administration of
blocking antibodies; animals so treated develop vascu-systems is ultimately recruited to the rejection of xeno-
grafts (Bach et al., 1996; Parker et al., 1996). As important lar lesions similar to those seen in rejecting xenografts.
One advance in xenotransplantation during the past de-as those pathways may be in destroying xenografts,
the pathways are probably not unique to the xenograft cade was the transgenic expression of human comple-
ment regulatory proteins in pigs, the organs of whichrejection and, therefore, will not be discussed. Instead,
we shall focus on the elements of immune and inflamma- are far less susceptible to complement-mediated injury,
even when the human proteins are expressed at verytory systems that initiate xenograft reactions and that
might, thus, be construed as “recognizing” xenogeneic low levels (McCurry et al., 1995).
Xenoreactive Natural Antibodiescells.
Complement All mature immunocompetent mammals studied to date
have been found to have xenoreactive natural antibod-The complement system provides the most potent de-
fense against the acceptance of xenografts. Comple- ies. These antibodies are referred to as “natural” be-
cause they appear in the circulation prior to any knownment of humans and other mammals may be activated in
a xenograft by the alternative pathway or by the classical contact with foreign cells. Xenoreactive natural antibod-
ies in humans are of at least two types: (1) the poly-pathway (Platt et al., 1990). The alternative pathway of
complement is regulated by factor H, which inhibits the reactive natural antibodies and (2) the monoreactive
anti-carbohydrate antibodies. Polyreactive antibodies,association of C3b with factor B on homologous sur-
faces but not on some heterologous surfaces. Activation which are thought to be the product of B1 B cells, bind
to a variety of structures on foreign cell surfaces (Gellerof the alternative pathway of complement appears to
provide a primary barrier to xenotransplants between et al., 1993). Whether polyreactive antibodies initiate
immune reactions is uncertain, as the relatively weakmany combinations of donor and recipient species (Ta-
ble 2). In some settings, however, for example, in trans- affinity of these antibodies may diminish the effector
functions, such as complement activation. The type ofplants of porcine organs into baboons or humans, the
alternative pathway of complement is not spontane- xenoreactive antibodies thought to be of preeminent
importance in humans are monoreactive antibodies spe-ously activated, presumably because factor H is func-
tional across these species. Instead, complement acti- cific for Gala1,3Gal (Good et al., 1992; Sandrin et al.,
1993), a saccharide expressed on the cells of lowervation is triggered by xenoreactive natural antibodies
that fix C1q, initiating the classical pathway. In some mammals but not humans or apes (Galili et al., 1988).
Archtypic anti-Gala1,3Gal antibodies are specific forcombinations of donor and recipient species (e.g., ham-
ster-to-rat and monkey-to-baboon), complement is not that saccharide and a few related saccharides and acti-
vate complement upon binding (Parker et al., 1996). Anti-immediately activated by either the alternative or classi-
cal pathway. Gala1,3Gal antibodies appear to be members of a class
of antibodies that include the anti-blood group A andComplement Regulatory Proteins
Activation of complement on the surface of autologous B antibodies. These anti-carbohydrate antibodies are
thought to arise during the first years of life, owing tocells is controlled in part by complement regulatory pro-
teins that are integral components of cell membranes. stimulation by gut bacteria with the host (Galili, 1993),
but other mechanisms of stimulation of B cells may alsoThese proteins include decay-accelerating activator
(CD55), which promotes the dissociation of C3 con- be involved.
Neutrophilsvertases (C3bBb and C4b2a), membrane cofactor protein
(CD46), which serves as a cofactor for factor I–mediated Neutrophils are generally thought to be recruited into
tissues as a response to inflammatory mediators andinactivation of C3b and C4b, and membrane inhibitor
of reactive lysis (CD59). This inhibits assembly of the through formation of C3bi on foreign cell surfaces. How-
ever, there may also exist primary interactions betweenmembrane attack complex (C5b678-polyC9). The com-
plement regulatory proteins may function in a species- neutrophils and xenogeneic cells that might precede
inflammation. For example, human neutrophils attachspecific manner, providing a mechanism of self–nonself
discrimination as a result of which a xenograft may be to porcine endothelial cells and activate the cells inde-
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Table 2. Examples of Experimental Xenografts
Donor Recipient Organ Rejection Pathologya Homology
Hamster rat heart 4 days AVR 87%
Guinea pig rat heart 12 min HAR 74%
Pig dog kidney 20 min HAR 89%
Pig baboon kidney 1.5 hr HAR 75%
Old world monkey baboon heart 6 days AVR 87%
New world monkey baboon heart 1 hr HAR 74%
Homology is based on identity of amino acid sequence of cytochrome b.
a AVR, acute vascular rejection; HAR, hyperacute rejection.
pendently of xenoreactive antibodies, complement, or cultures. This limited T cell response to xenogeneic stim-
ulation has been attributed to three factors: (1) a limitedother plasma mediators (Al-Mohanna et al., 1997).
Macrophages ability of T cell receptors to “directly” recognize foreign
MHC, owing to MHC restriction; (2) incompatibility ofMacrophages, like neutrophils, are expected to be
recruited into xenografts in response to inflammatory foreign cytokines with responder T cells; and (3) incom-
patibility of costimulatory molecules between speciesmediators. However, macrophages have also been pro-
posed to interact directly with xenografts and indepen- (Alter and Bach, 1990; Moses et al., 1992). Studies in a
number of laboratories, however, have shown that, whiledently of inflammatory mediators (Bach et al., 1996).
For example, Bach et al. (1996) has described primary one or more of these defects may exist in a given system,
T cells do in fact respond to direct presentation of xeno-interactions of human macrophages with porcine endo-
thelial cells. The primary interaction of macrophages geneic antigens by foreign MHC (Murray et al., 1994;
Rollins et al., 1994), presumably through the use of alter-with human cells appears to be mediated by lectins
expressed by the human macrophages, which are stim- native costimulatory pathways and cross-reactive prop-
erties of T cell receptors. T cells may also respond inulated by endothelial cell saccharides. Once stimulated
by this or other interactions, the macrophage may initi- vitro to foreign peptides presented by self-APC (Dorling
et al., 1996). Although the nature and intensity of T cellate coagulation through the elaboration of tissue factor.
Thrombin responses to xenotransplantation are still not com-
pletely known, there is increasing agreement that re-Thrombin triggers coagulation and a range of inflamma-
tory processes. Thrombin may be generated spontane- sponse is likely to be of an intensity equal to or greater
than the response to allotransplantation. We have pos-ously on porcine cell surfaces, owing to incompatibility
of porcine thrombomodulin with human thrombin and tulated that such an intense cellular immune response
reflects one or more of three mechanisms: (1) directprotein c, incompatibility of porcine tissue factor path-
way inhibitor with human factor Xa, or to other factors recognition of foreign MHC and heightened indirect re-
sponse to a diverse set of antigenic peptides presented(Jurd et al., 1996; Lawson and Platt, 1996; Ierino et al.,
1998). So generated, thrombin might activate platelets by self-MHC, (2) an amplifying effect of humoral immu-
nity and inflammation on cellular immune responses,and/or endothelial cells, leading to inflammation, tissue
injury, and the manifestations of rejection. and (3) limitation in recruitment and manifestation of
immunoregulatory pathways (Platt, 1998).Platelets
Human platelets do not “naturally” react with porcine Natural Killer Cells
Natural killer cells are notably cytotoxic for xenogeneicendothelial cells; however, when stimulated by small
amounts of thrombin, human platelets can stimulate cells (Inverardi et al., 1992). The mechanisms that give
rise to cytotoxicity are thought to include the following:porcine endothelial cells to produce tissue factor,
E-selectin, and other products typical of “activated en- (1) failure of MHC class I on the xenogeneic target to
interact with killer inhibitory receptors of the natural killerdothelial cells” (Bustos and Platt, 1997; Bustos et al.,
2001). The interaction of human platelets with porcine cells, (2) stimulation of Fcg II receptors on NK cells by
xenoreactive IgG bound to xenogeneic cells, and (3)endothelial cells that accounts for this reaction may be
several, but surface expression of IL-1a appears to be stimulation of lectin receptors on NK cells by saccha-
rides such as Gala1,3Gal on the xenogeneic target cellsespecially important. Platelets must also be recruited
and activated by porcine von Willebrand factor, which (Inverardi et al., 1997; Artrip et al., 1999). Although most
attention has focused on the possibility that natural killerhas been found to spontaneously activate human
platelets. cells may attack and destroy xenogeneic transplants,
recent studies suggest that natural killer cells may alsoT Cells
T cells clearly have the ability to recognize and destroy promote antigen presentation and, thus, elicited im-
mune responses directed against the xenograft (Smythxenografts, as demonstrated by the fact that xenografts
survive and grow in nude but not in wild-type mice. To et al., 1999).
which extent and by what mechanism T cells recognize
xenogeneic cells, however, has been a matter of contro-
versy. Work in the 1970s and 1980s suggested profound The Rejection of Xenografts: Manifestations
and Mechanismsdefects in T cell responses to xenogeneic cells (Lindahl
and Bach, 1976). These conclusions were based on the Like the immunological barrier to allotransplantation, the
immunological barrier to xenotransplantation is condi-observation that T cells respond poorly or not at all
to stimulation by xenogeneic APC in mixed leukocyte tioned to a large extent by the manner in which the
Immunity
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however, they are especially vulnerable to vascular
types of rejection listed in Figure 1B. Because of the
consuming interest in organ xenotransplantation, we
shall discuss vascular rejection in some detail.
Hyperacute Rejection
Organs transplanted between some species may be
susceptible to hyperacute rejection (Table 2). Hyper-
acute rejection begins within minutes of the perfusion
of a newly transplanted organ by the blood of the recipi-
ent and leads to the loss of graft function and destruction
of the organ within a period of hours, characterized by
formation of platelet thrombi and bleeding into the graft.
The speed and devastating impact of hyperacute rejec-
tion make it arguably the severest of immune responses.
Figure 1. The Biological Responses to Xenotransplantation The development of hyperacute rejection depends
(A) The barrier to cell and tissue xenotransplantation. Xenografts absolutely on the activation of complement on endothe-
consisting of isolated cells or tissues may fail initially because en-
lial cells of the graft. Although xenoreactive antibodies,graftment does not occur and subsequently because of cellular
neutrophils, macrophages, thrombin, and NK cells mayrejection.
react directly with porcine cells in vitro, as described in(B) The barrier to organ xenotransplantation. Organ xenografts are
susceptible to the sequence of rejection reactions listed in the figure. Table 1, none of these elements can trigger hyperacute
Under some conditions, a state of accommodation occurs in which rejection in the absence of complement. In most organ
the organ does not undergo acute vascular rejection, despite the xenografts, complement is activated through the alter-
existence of antibodies directed against the xenograft donor. native pathway, as discussed in Table 1. Activation of
(Adapted from Graft 1:19–24, 1998, with permission from Landes
complement by the alternative pathway leads to theBioscience and Graft).
rapid accumulation of C3 convertase on endothelium
and to the severest forms of hyperacute rejection
known. In xenografts such as pig-to-primate xenografts,transplant derives its blood supply (Figure 1). The impor-
complement is not initially activated by the alternativetance of the type of vascularization in determining the
pathway but rather by the binding of complement-fixingnature of immune responses is nowhere more important
xenoreactive antibodies. Activation of complement bythan in xenotransplantation. Grafts consisting of cells,
xenoreactive antibodies eventuates in hyperacute rejec-such as hepatocytes, derive a blood supply mainly by
tion reactions that are less florid and are easier to controlthe ingrowth of blood vessels of the recipient. Trans-
than reaction initiated by the alternative pathway.plants consisting of tissues, such as pancreatic islets
The mechanism by which complement activation onor skin, have some blood vessels that form by the spon-
blood vessels gives rise to hyperacute rejection involvestaneous anastomosis of donor and recipient capillaries
the assembly of terminal complement complexes. The
and some that form entirely by the ingrowth of recipient
need for formation of terminal complement complexes
vessels. Transplanted organs such as heart or kidney
is suggested by the observation that hyperacute re-
contain a vascular system entirely of donor origin. Trans-
jection of xenografts and allografts does not occur in
plants such as bone marrow, which are infused into C6-deficient recipients (Brauer et al., 1993). Although
vessels, are ultimately nourished by blood vessels of the xenoreactive antibodies, neutrophils, macrophages,
recipient, although the transplants are also, like organ thrombin, and NK cells may react directly with porcine
transplants, exposed directly to blood of the recipient. cells in vitro as described above, none of these elements
The first barrier to cell and tissue xenotransplantation can trigger hyperacute rejection in the absence of com-
is nonimmunological (Figure 1A). In fact, the ability of plement. On the other hand, morphological evidence
xenogeneic cells or tissue transplants to “take” in a that endothelium remains intact, at least early in the
foreign microenvironment depends first on the ability to course of hyperacute rejection (Figure 2), and the failure
sustain angiogenesis. New growth of blood vessels may of expression of CD59 to influence the occurrence of
be impaired by incompatibility of donor cells and recipi- hyperacute rejection (Diamond et al., 1996) suggests
ent growth factors (Gritsch et al., 1994). A cell or tissue that cytotoxicity is not an essential step in the pathogen-
xenograft might also fail to sustain angiogenesis due esis of that reaction. Instead, the rapid assembly of
to nonresponsiveness of the recipient endothelium to terminal complement complexes on endothelial sur-
donor angiogenesis factors. faces causes the endothelial cells to alter their shape
Xenogeneic cells and tissues that successfully engraft and retract one from the other, giving rise to interendo-
are subject to cellular rejection. Although the cellular thelial gaps and, thus, to a loss of endothelial integrity
immune response to a tissue xenograft may differ in (Saadi and Platt, 1995). The loss of endothelial integrity
ways described above from the cellular immune re- can be induced by C5b67, accounting for the failure of
sponse to an allograft, the response to a xenograft is CD59 to prevent it. The loss of endothelial integrity is
largely unaffected by humoral immunity. Consistent with also transient, counting for the need of rapid assembly
this concept, cell and tissue xenografts can be main- of the terminal complement complexes.
tained for months with immunosuppressive therapies Hyperacute rejection can be prevented by any means
such as cyclosporin A, which predominantly affects cel- that slow or prevent the activation of complement in the
lular immunity (Gunsalus et al., 1997). transplant. In pig-to-primate xenografts, such means
include the depletion of xenoreactive antibodies fromOrgan xenografts are also subject to cellular rejection;
Review
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Figure 2. The Pathology of Hyperacute Rejection
Hyperacute rejection of a porcine heart transplanted into a baboon. Hyperacute rejection is characterized by the widespread formation of
thrombi consisting largely of platelets and bleeding into the graft. The immunopathology of the reaction reveals the presence of the membrane
attack complex on blood vessels in the graft, as the assembly of terminal complement complexes is an essential step in the pathogenesis
of this reaction (see text).
the circulation of the recipient and the inhibition of com- lant state that in turn could lead to diffuse intravascular
coagulation and, thus, to ischemia of the graft. Macro-plement reactions. One means of controlling comple-
ment is the expression of human complement regulatory phages and NK cells have been thought by some to play
a primary role, as they are often found in acute vascularproteins in the xenograft donor.
Acute Vascular Rejection rejection in rodents (Bach et al., 1996). However, in these
rodent models (Nagayasu et al., 2000) and in porcine-If the complement system of a xenograft recipient is not
rapidly activated in the graft, such as hamster hearts to-primate xenografts, inflammatory cells do not appear
until the tissue lesions are far advanced, and an inhibi-transplanted into rats, or if the hyperacute rejection is
prevented, the xenograft may be subject to acute vascu- tion of the cells using monoclonal antibodies has little
or no effect on graft outcome, suggesting that, althoughlar rejection. Acute vascular rejection emerges over a
period of days to weeks and is characterized by endo- whole inflammatory cells may contribute to tissue injury,
they may not initiate the reactions. Similarly, while coag-thelial swelling, focal ischemia, and intravascular coagu-
lation (Figure 3). Acute vascular rejection, sometimes ulation of human plasma can be directly initiated by
porcine cells, spontaneous generation of thrombin maycalled delayed xenograft rejection or acute humoral re-
jection, causes destruction of a xenograft over a period not be vital to the pathogenesis of acute vascular rejec-
tion, as it is not observed over periods of weeks toof days to weeks and is now widely seen as the major
hurdle to the clinical application of organ xenotransplan- months in xenografts with accommodation (Cozzi et al.,
2000; Lin et al., 2000). There is an emerging consensustation (Platt, 1998).
A number of the factors listed in Table 1 have been that acute vascular rejection is initiated by xenoreactive
antibodies. This idea is suggested by the observationimplicated as potentially initiating acute vascular rejec-
tion (Platt et al., 1998). These factors are postulated to that depletion of all Ig or only anti-Gala1,3Gal Ig in ways
that leave complement and coagulation cascades andgive rise to endothelial cell activation and to a procoagu-
Figure 3. The Pathology of Acute Vascular Rejection
The pathology of acute vascular rejection is characterized by endothelial thickening, ischemia, and thrombosis, the thrombi consisting largely
of fibrin. The immunopathology of acute vascular rejection commonly reveals antibodies of the recipient deposited along the endothelial lining
of blood vessels. The figure shows acute vascular rejection of a porcine heart, transgenic for human decay-accelerating factor (DAF) and
human CD59, that was transplanted into a baboon. Expression of DAF and CD59 prevents the occurrence of hyperacute rejection, allowing
acute vascular rejection to ensue over a period of 5–10 days.
Immunity
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inflammatory cells intact delays or prevents acute vas- the transplants was followed by prolonged function of
the transplants after the return of the antibodies to thecular rejection (Lin et al., 1998a, 2000). Although acute
vascular rejection can be caused by anti-Gala1,3Gal circulation. Accommodation has been observed in ro-
dent models of xenotransplantation (Lin et al., 1998b,antibodies, there is little doubt that other xenoreactive
antibodies will be found also to cause this type of rejec- 1999) and in porcine organs transplanted into baboons,
where the organs express human complement regula-tion, as it invariably occurs in monkey-to-baboon xeno-
grafts (Table 2). tory proteins and the xenoreactive antibodies are de-
pleted temporarily from the circulation of the xenograftHow anti-donor antibodies trigger acute vascular re-
jection is still uncertain. Xenoreactive antibodies such recipient (Lin et al., 1998a, 2000). The development of
accommodation may be important for the successfulas anti-Gala1,3Gal may bind to biologically active struc-
tures such as porcine integrins, directly perturbing the engraftment of xenogeneic organs, because these or-
gans contain numerous antigens that could evoke hu-function of endothelium (Holzknecht and Platt, 1995;
Palmetshofer et al., 1998). Xenoreactive antibodies moral immune responses.
We originally postulated that accommodation may re-might also cause acute vascular rejection by activating
small amounts of complement in the graft. For example, flect one or more of three changes following organ trans-
plantation: (1) a change in the nature of xenoreactiveassembly of small amounts of terminal complement
complexes on endothelial cells induces the production antibodies, (2) a change in the antigen impairing anti-
body binding, and (3) induction of cellular resistance toof IL-1a, which acts on endothelial cells in an autocrine
manner to induce the expression of tissue factor, plas- humoral injury (Platt et al., 1990; Parker et al., 1996).
There is, at present, no evidence that accommodation inminogen activator inhibitor Type I, and various other
inflammatory factors (Saadi et al., 1995, 2000). Although primates is associated with production of xenoreactive
antibodies different from the antibodies produced inacute vascular rejection occurs in C6-deficient recipi-
ents and in recipients treated with complement inhibi- acute vascular reaction. Nor is there compelling evi-
dence of a change in antigens in accommodation oftors, the transplanted organ may in some cases produce
enough complement to allow the reactions to proceed. xenografts, although modulation of the Forssman anti-
gen has been described in one model of accommodationOne factor in addition to antibodies that may initiate
acute vascular rejection is the reaction of platelets with (Yuzawa et al., 1995). On the other hand, accommoda-
tion in both rodents and pig-to-primate xenografts ap-endothelium. Stimulated with small amounts of thrombin
or with porcine von Willebrand factor, platelets express pears to be associated with expression of various anti-
apoptotic proteins and heme oxygenase-1 (Bach et al.,IL-1a, which can trigger endothelial cell activation
(Bustos and Platt, 1997; Bustos et al., 2001). 1997). These changes may be characteristic of a broader
phenomenon in which cells exhibit reversal of noxiousSeveral approaches might be applied to the preven-
tion or treatment of acute vascular rejection. To the pathways (Table 3) (Holzknecht and Platt, 2000).
Table 3 lists three of the general mechanisms by whichextent that anti-Gala1,3Gal antibodies trigger acute vas-
cular rejection, the induction of immunological tolerance biological responses might be reversed in accommoda-
tion. In the first mechanism, the cell acquires specificto Gala1,3Gal or the elimination of that saccharide from
transplants might prevent the initiation of that process. nonresponsiveness to the offending agonist. An exam-
ple of such a response is the desensitization of G pro-Tolerance to Gala1,3Gal has been induced by various
means in mice that make “natural” anti-Gala1,3Gal anti- tein–coupled receptors, which is mediated by phosphor-
ylation. This mechanism is specific for the offendingbodies (Bracy et al., 1998; Yang et al., 1998; Ohdan et
al., 1999). Whether tolerance could be effectively applied agonist and has thus been called “homologous” (Sibley
and Lefkowitz, 1985). The second mechanism involvesin humans is still uncertain. The recent cloning of pigs
in various laboratories and evidence that homologous biochemical changes that inhibit the pathway triggered
by the offending agonist. An example of this mechanismrecombination can be used in sheep to replace the factor
VIII locus raises the possibility that Gala1,3Gal might be can be found in cells exposed to TNFa, such cells pro-
duce IkB, which in turn inhibits NF-kB (Read et al., 1994).knocked out in pigs (Polejaeva et al., 2000). Indeed, this
goal is being sought by various companies interested This mechanism might be seen as a response to a num-
ber of agonists other than the primary agonist, and, thus,in marketing organs for use in xenotransplantation. Of
course, if antibodies other than those directed against it is called “heterologous.” A third mechanism, which
we call “protection,” involves production of substancesGala1,3Gal should induce acute vascular rejection, then
these approaches would ultimately fail. In this case, that inhibit the toxic effects of the agonist without inhib-
iting receptor signaling or the distal pathway. Expressiontolerance might be induced to a broader spectrum of
antigens by transplantation of hematopoietic stem cells of heme oxygenase-1, ferritin, and antiapoptotic pro-
teins are examples of this mechanism.of the donor species into the recipient (Sachs and
Sablinski, 1995). Still another approach to preventing Chronic Rejection
Whether or not and to what frequency chronic rejectionacute vascular rejection of xenotransplants may involve
the induction of accommodation. would occur in a vascularized xenograft is uncertain
because of the difficulties in overcoming acute vascularAccommodation
Accommodation is an acquired resistance to humoral- rejection. However, certain working hypotheses can be
advanced. Work in experimental allografts has shownmediated injury and acute vascular rejection of an organ
graft. Accommodation was first observed in the trans- that chronic rejection can be induced by anti-donor anti-
bodies (Hancock et al., 1998), and it can be anticipatedplantation of kidneys across blood group A and B barri-
ers (Platt et al., 1990). In these cases, transient removal that anti-donor antibodies might also contribute to the
development of chronic rejection of xenografts. If com-of anti-blood group antibodies from the recipients of
Review
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Table 3. Mechanism of Reversal of Biological Reactions that Might Account for Accommodation
Mechanism Example Specificitya
Regulation G protein–coupled receptor homologous
Negative feedback TNFa ) IkB heterologous
Protection Hemeoxygenase-1 1 ferritin heterologous
a Mechanisms specific for a given agonist are called homologous. Mechanisms that might be induced by various agonists are called heterol-
ogous.
plement activation on endothelial cells or smooth mus- of immune complexes with the immune system of the
recipient.cle cells induces proliferation of the cells (Benzaquen
et al., 1994) and the development of chronic lesions, The extent to which innate humoral responses pro-
mote cellular immune responses is unknown. The impor-one might also anticipate such lesions in vascularized
xenografts. Whether cell-mediated immunity would tance of humoral responses to a transplant donor are
suggested by the observations that (1) preexisting anti-cause chronic rejection of xenografts, as it does in allo-
grafts, is unknown. On the other hand, to the extent that bodies, such as anti-blood group antibodies, against
clinical organ transplant donors are associated with anonimmunologic causes of chronic rejection, such as
preservation injury and infection, contribute to chronic high risk of cellular rejection; and (2) cellular immune
responses to experimental allografts are inhibited byrejection, that problem might be less in an organ xeno-
graft. inhibition of complement activation (Pratt et al., 1996).
On the other hand, the presence of antibodies against
a xenograft donor does not necessarily promote earlyXenotransplantation as a Model for the Connection
of Innate and Adaptive Immune Responses and severe cellular immune responses in xenotransplan-
tation, as accommodated organ xenografts (Lin et al.,Innate immunity is thought to facilitate the development
of adaptive immune responses (Fearon and Locksley, 1998a) and cellular xenografts do not seem more sus-
ceptible than allografts to cellular rejection (Pierson et1996; Medzhitov and Janeway, 1997). For example, acti-
vation of complement can promote the development of al., 1989; Gunsalus et al., 1997).
a T cell–dependent B cell response. However, whether
innate immunity amplifies elicited immune responses Modeling the Immunological Barrier
to Xenotransplantationor allows elicited immune responses to occur under
suboptimal conditions is not certain. Given the intensity Progress in understanding the immunological barrier to
xenotransplantation has allowed the development ofof the innate immune response to xenotransplantation—
activation of the alternative complement pathway and/ new models that might be applied to the human setting.
Because only humans, apes, and old world monkeysor binding of xenoreactive antibodies to xenogeneic
cells—the xenotransplant might offer a good model sys- have anti-Gala1,3Gal antibodies, it has been necessary
to conduct much of the research in xenotransplantationtem in which to explore the contribution of innate immu-
nity to adaptive immune responses. Figure 4 illustrates in primate model systems. Although the use of primates
offers clear advantages over such classical models suchthe depositing of immune complexes in the spleen of a
xenotransplant recipient (Holzknecht et al., 2001). The as guinea pig-to-rat xenotransplantation in which com-
plement is activated by the alternative pathway indepen-outcome of xenotransplantation is significantly im-
proved by removal of the spleen, and this may reflect dent of xenoreactive antibodies, the use of primates also
has serious limitations. Primates are far more difficultthe potential role of the spleen as a site for interaction
Figure 4. The Connection of Innate and Adaptive Immunity to Xenotransplantation
Immune complexes form through the reaction of anti-Gala1,3Gal antibodies of the xenograft recipient with glycoproteins such as von Willebrand
factor (vWf) secreted from the xenograft. The immune complexes deposit in the liver (data not shown) and in the spleen, as illustrated in the
figure. The deposition of immune complexes in the spleen may promote elicited immune responses against porcine proteins. Baboon C3 and
porcine von Willebrand factor (arrowheads) are detected by immunofluorescence.
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to manipulate and to monitor than other experimental tion in relevant xenograft models. However, one aspect
of this problem does offer encouragement. When a clini-animals and are not fully satisfactory for studying cross-
species infection. Porcine endogenous retrovirus, which cal allograft fails, the human patient may have no alter-
native organ available. If a clinical xenograft were to fail,has been recently considered as a possible cause of
zoonosis, may be less able to infect the cells of nonhu- another might be put in place.
We have focused this review on the immunologicalman primates than the cells of humans.
Although nonhuman primates would seem to be ad- aspects of xenotransplantation, and, because of con-
straints of space, we have not considered some impor-vantageous for the study of complement-mediated re-
actions, it is still uncertain that the complement system tant issues in detail. We shall, nevertheless, briefly sum-
marize some of these issues. Critical to the success ofof these animals would be fully susceptible to control
by human complement regulatory proteins expressed xenotransplantation is the susceptibility of the recipient
to infection. One particular aspect of this is the possibil-in transgenic pigs. In the case of incompatibility, the
use of primates as a model for xenotransplantation will ity of transspecies infection and the risk of zoono-
sis. One important consideration is the assessment ofbe further limited.
One model of potential value has emerged by the whether this risk is balanced by the benefits that xeno-
transplantation would bring to society. Besides organ,targeted disruption of a1,3-galactosyl transferase in the
mouse (Thall et al., 1995). a1,3-galactosyl transferase tissue, or cellular replacement, xenotransplantation
might be used to other purposes, for example, to modu-knockout mice are the only small mammals that make
anti-Gala1,3Gal antibodies. Although these mice have late immunity. These possibilities may someday allow
us to custom modify the immune system for the preven-been used to advantage in some recent investigations,
the mice vary in certain significant ways from humans tion and treatment of human disease.
and higher primates. For example, a1,3-galactosyl
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